Literature DB >> 1993748

Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120.

M Gilbert1, J Kirihara, J Mills.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) that can measure picogram quantities of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein 120 (gp120) in cell culture medium or body fluids has been developed. Recombinant, soluble CD4 immobilized in microtiter trays was used to capture gp120, which was then detected with polyclonal sheep antibody to gp120 followed by biotinylated rabbit anti-sheep immunoglobulin G and an avidin-alkaline phosphatase indicator system. With a reference recombinant gp120, the assay showed a linear relationship between optical density and concentrations ranging from 60 to 6,000 pg/100-microliters well; precision of the assay varied with the concentrations and ranged from +/- 40% with amounts smaller than 200 pg to +/- 10% with amounts larger than 200 pg. In a group of coded samples containing 60 pg (approximately 10(7) molecules) of reference gp120, the assay correctly identified the samples as containing gp120 99% of the time, with no false-positive results recorded for blank samples. Recombinant gp120 prepared in another cell culture system demonstrated a binding coefficient 13-fold lower than that of reference gp120. Mixing standard amounts of reference gp120 with increasing concentrations of human sera reduced assay sensitivity, although the linear relationship between gp120 concentration and optical density remained. With this assay we were able to detect gp120 in HIV-1 suspensions prepared from cultured lymphoblastoid cells and in the sera of HIV-1-infected patients. This ELISA for gp120 should be useful for studying the biological role of gp120 in HIV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993748      PMCID: PMC269718          DOI: 10.1128/jcm.29.1.142-147.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells.

Authors:  P J Gomatos; N M Stamatos; H E Gendelman; A Fowler; D L Hoover; D C Kalter; D S Burke; E C Tramont; M S Meltzer
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Inhibition of soluble CD4 therapy by antibodies to HIV.

Authors:  L N Callahan; M A Norcross
Journal:  Lancet       Date:  1989-09-23       Impact factor: 79.321

4.  Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation.

Authors:  R S Mittler; M K Hoffmann
Journal:  Science       Date:  1989-09-22       Impact factor: 47.728

5.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  Inhibitory influences of envelope glycoproteins of HIV-1 on normal immune responses.

Authors:  N Chirmule; V Kalyanaraman; N Oyaizu; S Pahwa
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

8.  Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.

Authors:  B Ardman; M Kowalski; J Bristol; W Haseltine; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus.

Authors:  R A Ezekowitz; M Kuhlman; J E Groopman; R A Byrn
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  23 in total

1.  Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines.

Authors:  Jenna Rychert; Daryld Strick; Sue Bazner; James Robinson; Eric Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08-19       Impact factor: 2.205

2.  Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites.

Authors:  Bin Yu; Dora P A J Fonseca; Sara M O'Rourke; Phillip W Berman
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

3.  Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.

Authors:  R Ahmad; S T Sindhu; E Toma; R Morisset; J Vincelette; J Menezes; A Ahmad
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

Review 4.  Fate of microglia during HIV-1 infection: From activation to senescence?

Authors:  Natalie C Chen; Andrea T Partridge; Christian Sell; Claudio Torres; Julio Martín-García
Journal:  Glia       Date:  2016-11-26       Impact factor: 7.452

5.  Determination of the optimal cutoff value for a serological assay: an example using the Johne's Absorbed EIA.

Authors:  S E Ridge; A L Vizard
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

6.  Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy.

Authors:  Daniel S Green; David M Center; William W Cruikshank
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

7.  Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration.

Authors:  Erik R Kline; Dean J Kleinhenz; Bill Liang; Sergey Dikalov; David M Guidot; C Michael Hart; Dean P Jones; Roy L Sutliff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

8.  Association of T cell and macrophage dysfunction with surface gp 120-immunoglobulin-complement complexes in HIV-infected patients.

Authors:  V Daniel; C Süsal; R Weimer; R Zimmermann; A Huth-Kühne; G Opelz
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.

Authors:  Diana M Brainard; William G Tharp; Elva Granado; Nicholas Miller; Alicja K Trocha; Xiang-Hui Ren; Brian Conrad; Ernest F Terwilliger; Richard Wyatt; Bruce D Walker; Mark C Poznansky
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 10.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.